Gleolan Granted Orphan-Drug Status By FDA For Ovarian Cancer Surgery

NX Development Corp. (NXDC) has recently marked a significant achievement in the medical field by obtaining orphan-drug status from the U.S. Food and Drug Administration (FDA) for Gleolan (aminolevulinic acid HCl). This prestigious designation is for the "real-time detection and visualization of epithelial ovarian tumors during debulking surgery," highlighting the innovative approach towards enhancing cancer treatment.

Dr. Salvatore DeSena, CEO of NX Development Corp., expressed his pride in this accomplishment, emphasizing the company's dedication to advancing Gleolan's applications in combating ovarian, fallopian tube, and primary peritoneal cancer. This development not only showcases NXDC's commitment to innovation but also its focus on providing tangible solutions to patients and surgeons facing the challenges of cancer treatment.

Dr. Ulrich Kosciessa, Chairman of the Board of NXDC and CEO of photonamic GmbH & Co KG. (Pinneberg, Germany), the parent company of NXDC, also highlighted the broader implications of this milestone. He pointed out the potential for expanding the use of aminolevulinic acid HCl in fluorescence-guided surgery beyond national borders, aiming to support healthcare professionals and patients worldwide in their fight against cancer.

Gleolan is recognized clinically for its role in visualizing malignant glioma tissue during surgery. It serves as an optical imaging agent for patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging), aiding in the identification of malignant tissue during surgical procedures. This recent FDA designation underscores Gleolan's importance and effectiveness in a new application area, further solidifying its position in the field of fluorescence-guided surgery.

About NX Development Corp.: A wholly-owned subsidiary of photonamic GmbH & Co. KG., itself a member of the SBI Holdings Inc. Group (Tokyo, Japan), NX Development Corp. is at the forefront of revolutionizing cancer care. The company is committed to introducing innovative solutions and making significant strides in fluorescence-guided surgery to improve patient outcomes.

About Gleolan: As an optical imaging agent, Gleolan plays a crucial role in the surgical treatment of certain types of cancer by enabling the real-time visualization of malignant tissues, thereby assisting surgeons in more effectively identifying and removing cancerous cells.